Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models

Schiaffino, Stefano; Mammucari, Cristina

doi:10.1186/2044-5040-1-4

Skeletal Muscle

Table 3 Knockout and knock-in models of IGF1-Akt pathway components: effect on growth

From: Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models

Genotype¹	Viability	Growth phenotype	References
Igf1 null	Severe neonatal lethality	Severe growth retardation	[37–39]
Igf1 null in muscle (Mef2c-Cre)	Viable	Normal growth	[63]
Igf1 receptor null	Severe neonatal lethality	Severe growth retardation	[37, 39]
Igf1 receptor null in muscle (Mef2c-Cre)	Viable	Reduced body weight, reduced muscle fiber number and size	[63]
IRS1 null	Viable	Reduced growth (weight 30-60% of control)	[64, 122]
IRS2 null	Viable	Almost normal growth (birth weight 90% of control)	[65]
PI3K p85α + p55α + p50α null	Perinatal lethality		[66]
PI3K p85α + p55α + p50α null in heart & muscle (MCK-Cre)	Viable	Normal growth	[68]
PI3K p85β null	Viable	Normal growth	[67]
PI3K p85α + p55α + p50α null in heart & muscle (MCK-Cre) and p85β null	Viable	Reduced heart size but not muscle size	[68]
PTEN null in heart & muscle (MCK-Cre)	Viable	Cardiac hypertrophy but normal skeletal muscle growth; unaffected overload-induced muscle hypertrophy; improved muscle regeneration	[70, 71, 123]
PDK1 null	Embryonic lethality		[124]
PDK1 knock-in mutant unable to bind phosphoinositides	Viable	Reduced growth (weight 35% of control)	[125]
PDK1 null in heart & muscle (MCK-Cre)	Lethal at 5-11 weeks	Dilated cardiomyopathy but no change in muscle	[73]
Akt1 null	Viable but shorter life span	Mild growth retardation (weight 80% of control)	[74, 75]
Akt2 null	Viable	Normal growth	[76]
Akt1+Akt2 null	Neonatal lethality	Severe growth retardation (birth weight 50% of control), marked muscle atrophy	[77]
TSC1 null	Embryonic lethality		[126]
TSC2 null	Embryonic lethality		[127]
mTOR null	Embryonic lethality		[128, 129]
mTOR null in muscle (HSA-Cre)	Viable but premature death	Reduced postnatal growth due to reduced fast muscle growth, severe myopathy	[88]
Raptor null	Embryonic lethality		[6]
Raptor null in muscle (HSA-Cre)	Viable	Normal growth	[87]
Rictor null in muscle (HSA-Cre)	Viable	Reduced postnatal growth with severe myopathy and premature death	[87]
S6K1 null	Viable	Reduced growth (birth weight 80% of control), reduced muscle growth (fiber size 80% of control in adult mice)	[89, 117]
S6K2 null	Viable	Normal growth	[130]
S6K1+S6K2 null	Perinatal lethality	Reduced growth	[130]
4EBP1+4EBP2 null	Viable	Normal growth	[131]
FoxO1 null	Embryonic lethality		[132, 133]
FoxO1 null in muscle (HSA-Cre)	Viable	Normal growth, slow to fast switch in muscle	[134, 135]
FoxO3 null	Viable but female sterility	Normal growth	[133, 36]
FoxO4 null	Viable	Normal growth	[137]
FoxO3+FoxO4 null	Viable	Normal growth	[137]
MAFbx null	Viable	Reduced muscle atrophy after denervation	[92]
Murf1 null	Viable	Reduced muscle atrophy after denervation	[92]

¹ Promoters used to drive Cre recombinase expression: HSA = human skeletal actin; MCK = muscle creatine kinase; Mef2c = a promoter that lies 71 kb upstream of the first translated exon of the Mef2c gene and is sufficient to direct expression exclusively to skeletal muscle from embryonic day 8.5.

Back to article page

ISSN: 2044-5040

Contact us

General enquiries: journalsubmissions@springernature.com